FDA approves Bixlenvo to simplify complex HIV regimens

FDA has approved Bixlenvo (bictegravir/lenacapavir) as a complete replacement regimen for adults with HIV-1 who are virologically suppressed on stable antiretroviral therapy and have no known or suspected resistance to either component.

Both antiretrovirals were previously available, but not together in a fixed-dose product. Bictegravir is a component of Biktarvy, while lenacapavir is marketed as Sunlenca. Their combination in Bixlenvo creates a new single-tablet option for patients who have remained on complex therapy because resistance, tolerability, or other treatment considerations limited regimen simplification.

Bixlenvo combines an integrase inhibitor with a first-in-class capsid inhibitor and contains no nucleoside reverse transcriptase inhibitors. Before switching, clinicians will need to review resistance and treatment histories and assess potential drug interactions.

Approval was supported by the phase 3 ARTISTRY-1 and ARTISTRY-2 trials, in which switching to Bixlenvo maintained viral suppression at 48 weeks at rates comparable to continuing existing therapy. ARTISTRY-1 included extensively treated adults taking two to eleven pills daily; 67% had historical NRTI resistance, and 81% were receiving complex therapy because of antiretroviral resistance.

Initiation requires Bixlenvo plus 600 mg of oral Sunlenca on days 1 and 2, followed by Bixlenvo alone once daily beginning on day 3. Bixlenvo is contraindicated with dofetilide and strong CYP3A inducers. The most common adverse reactions were headache, nausea, and diarrhea.

“The approval is a significant advancement in HIV treatment, especially for individuals unable to benefit from guideline-recommended [single tablet regimens] due to challenges like pre-existing resistance or tolerability,” said Chloe Orkin, MD, lead investigator for ARTISTRY-1. “It expands tailored, simplified dosing to people whose needs were not fully met by existing single tablet therapies.”

Source: Gilead Sciences. (2026 Aug 27). U.S. FDA approves Gilead’s Bixlenvo, a new once-daily single tablet option for virologically suppressed adults with HIV, including those on complex regimens